Trump demands pharma CEOs lower drug prices within 60 days
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Leerink: 'We continue to recommend REGN shares'
August 4, 2025 10:20 AM EDTLeerink Partners analyst Andrew Berens reiterated an Outperform rating and $645.00 price target on Regeneron Pharma (NASDAQ: REGN).
The analyst comments "Bottom Line: We continue to recommend REGN shares based upon improving growth prospects and attractive valuation. We project 5-yr (2025-2030) CAGR rev +7% and EPS +10%. Mgmt emphasized Lynozyfics... More
